ClinicaliQ Trial Snapshot
- A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006) — Recruiting • Phase III • Respiratory / COPD / Asthma • NCT06883305.
- What is being tested: Tezepelumab, a thymic stromal lymphopoietin (TSLP) inhibitor monoclonal antibody, is being evaluated for efficacy and safety in adult patients with moderate to very severe COPD in a phase 3 randomised controlled trial using a double-blind, placebo-controlled design.
- Patient eligibility overview: The trial enrolls adults with moderate to very severe COPD across multiple centres; specific eligibility criteria define the disease severity range and patient characteristics required for participation in this multicenter study.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
Eligibility Snapshot
- : 1. ≥40 to ≤80 years old 2. COPD diagnosis ≥1 year, 3. Post-BD FEV1 ≥ 20% and ≤ 70% PN, FEV1/FVC 4.0 L/min or O2 saturation
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.